• Prochlorperazine-Induced Hemidystonia as an Acute Stroke Mim

  2026-04-13

  This article analyzes a reference study reporting the first documented case of prochlorperazine-induced hemidystonia presenting as an acute stroke mimic in a pregnant patient. The findings underscore the diagnostic challenges in emergency neurology and highlight the critical importance of differentiating true ischemic stroke from mimics, particularly in the context of time-sensitive interventions.

• DIDS: Advanced Strategies for Modulating Metastatic Cell Fat

  2026-04-12

  Explore the multifaceted applications of DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) in dissecting chloride channel function, tumor metastasis, and neuroprotection. This article uniquely connects mechanistic insights with protocol optimization for next-generation cancer and neuroscience research.

• FLT3-TAZ Signaling Drives Drug Resistance in BP-CML: Insight

  2026-04-12

  Shin et al. (2023) reveal that aberrant FLT3-TAZ signaling defines a high-risk, drug-resistant subgroup in blast phase chronic myeloid leukemia (BP-CML), independent of BCR::ABL1 mutations. The study demonstrates that targeting FLT3—using inhibitors—restores sensitivity to tyrosine kinase inhibitors and suggests novel therapeutic strategies for overcoming resistance.

• PPM-18 for iNOS Inhibition: Optimizing Inflammation Research

  2026-04-11

  PPM-18 (N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide) enables precise, reproducible inhibition of iNOS via NF-κB pathway modulation, advancing both in vitro and in vivo inflammation studies. This guide delivers actionable protocol enhancements, troubleshooting insights, and bridges the latest cardiovascular signaling research into translational sepsis workflows.

• Dovitinib (TKI-258): Applied Workflows in Cancer Research

  2026-04-11

  Dovitinib (TKI-258, CHIR-258) empowers researchers to dissect and inhibit complex RTK-driven oncogenic pathways with nanomolar precision. This guide delivers actionable workflows, troubleshooting strategies, and data-backed protocol enhancements for maximizing apoptosis induction and pathway analysis in cancer models.

• Perphenazine in Neuroimmune Research: Mechanistic Advance...

  2026-04-10

  Explore Perphenazine's unique role as a dopamine D2 receptor antagonist in neuroimmune and host-directed therapy research. This in-depth analysis uncovers new mechanistic insights and experimental strategies, offering a fresh perspective beyond traditional neuropharmacology.

• Perphenazine: Bridging Dopamine Antagonism, Mitochondrial...

  2026-04-09

  This thought-leadership article explores the multifaceted utility of Perphenazine (SKU B6157) as a dopamine D2 receptor antagonist for translational researchers. We dissect the mechanistic underpinnings of Perphenazine’s action in neuropharmacology, its role in mitochondria-mediated cell death, and its emerging promise in host-directed antibacterial therapies—highlighting new scientific vistas beyond conventional antipsychotic applications. Drawing on recent primary literature and expert-driven guidance, we provide strategic recommendations for experimental design, competitive positioning, and future innovation in neuropsychiatric and immunological research.

• Perphenazine: Dopamine D2 Antagonist for Neuropharmacolog...

  2026-04-08

  Perphenazine is a potent dopamine D2 receptor antagonist and phenothiazine derivative for advanced neuropharmacology and host-pathogen research. Its multi-receptor binding and mitochondria-mediated cell death induction enable rigorous study of schizophrenia, opioid tolerance, and antibacterial host responses.

• Perphenazine: Multifunctional Dopamine Antagonist for Nex...

  2026-04-08

  Explore Perphenazine's unique role as a dopamine D2 receptor antagonist and phenothiazine derivative in advanced neuropharmacology and host-directed antibacterial research. This in-depth analysis reveals emerging mechanisms—beyond conventional applications—for cell death induction, opioid tolerance suppression, and immune modulation.

• Perphenazine as a Translational Research Catalyst: Mechan...

  2026-04-07

  This thought-leadership article delivers an in-depth exploration of Perphenazine’s mechanistic versatility, spanning dopamine D2 receptor antagonism, mitochondria-mediated cell death induction, opioid tolerance suppression, and emerging host-directed antibacterial strategies. By integrating cutting-edge experimental findings, competitive benchmarking, and strategic workflow guidance, we empower translational researchers to leverage APExBIO’s Perphenazine (SKU B6157) as a scenario-driven, multi-receptor antagonist for advanced neuropharmacology and immunomodulation research. This piece escalates the conversation beyond standard product pages by connecting receptor pharmacology to actionable translational opportunities and future-ready research paradigms.

• Perphenazine: From Dopamine Antagonism to Host-Directed T...

  2026-04-07

  This thought-leadership article positions Perphenazine as a bridge between advanced neuropharmacology and host-directed antibacterial strategies. By dissecting its multimodal receptor profile and recent mechanistic discoveries—including mitochondrial cell death induction and macrophage immune potentiation—this piece provides translational researchers with actionable insights, competitive context, and strategic guidance for next-generation applications. Drawing on the latest open-access research and internal content assets, this article differentiates itself from standard product pages by offering a visionary roadmap for Perphenazine’s research and therapeutic potential.

• Perphenazine Beyond Neuropharmacology: Mechanistic Insigh...

  2026-04-06

  This thought-leadership article examines Perphenazine’s evolving role as a research tool, integrating mechanistic depth with strategic direction for translational scientists. By dissecting its multi-receptor antagonism, mitochondria-mediated cell death, opioid tolerance suppression, and emerging applications in host-directed antibacterial strategies, we provide a roadmap to leveraging APExBIO Perphenazine (B6157) for future-ready research in neuroscience, immunology, and infectious disease.

• Perphenazine as a Multifaceted Dopamine Antagonist: Advan...

  2026-04-06

  Explore the multifaceted mechanisms and advanced research applications of Perphenazine, a potent dopamine D2 receptor antagonist. This article delves into its unique role in both neuropharmacology and host-pathogen interaction studies, revealing novel therapeutic and investigative pathways for schizophrenia, psychosis, and bacterial infections.

• Perphenazine: Dopamine D2 Antagonist for Neuropharmacolog...

  2026-04-05

  Perphenazine stands out as a versatile dopamine D2 receptor antagonist, empowering researchers in neuropharmacology, schizophrenia, and host-pathogen interaction studies. Its unique receptor binding profile and proven ability to induce mitochondria-mediated cell death or suppress opioid tolerance make it indispensable for advanced bench workflows and translational applications.

• Perphenazine: A Mechanistic Powerhouse Driving Next-Gen N...

  2026-04-04

  This thought-leadership article unpacks the mechanistic, experimental, and translational potential of Perphenazine—a dopamine D2 receptor antagonist—across neuropharmacology, cell death research, and innovative host-directed therapies. It offers strategic guidance for researchers seeking reproducibility, mechanistic insight, and workflow integration, and positions APExBIO’s Perphenazine as a benchmark research compound.

444 records 21/30 page Previous Next First page 上5页 2122232425 下5页 Last page